atezolizumab + bevacizumab + ADG126

This combination consists of three agents: - **Atezolizumab**: a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), classified as an anti-PD-L1 immune checkpoint inhibitor. It blocks PD-L1 interaction with PD-1 and CD80, lifting suppression of cytotoxic T cells, which facilitates anti-tumor immune responses. Used widely in immunotherapy for a range of cancers including lung, bladder, and liver cancers[1][3][5][7]. - **Bevacizumab**: a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis. By binding to VEGF-A, it prevents the growth of blood vessels necessary for tumor nourishment. Approved for use in various cancers. - **ADG126**: a novel, fully human monoclonal IgG1 antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), developed using Adagene's SAFEbody® platform. ADG126 is uniquely masked via a protease-cleavable peptide, which activates selectively in the tumor microenvironment. Once active, it binds a unique CTLA-4 epitope, primes T cells by partially blocking ligand, and depletes immunosuppressive regulatory T-cells (Tregs) via potent antibody-dependent cellular cytotoxicity/phagocytosis. This design aims for high tumor specificity and reduced systemic toxicity[2][4]. This combination is currently under clinical evaluation, particularly in solid tumors such as metastatic microsatellite stable colorectal cancer (MSS CRC), aiming to maximize immune-mediated anti-tumor activity while managing toxicity.

Other names

atezolizumabbevacizumabADG126ADG-126ADG 126